Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ROFLUMILAST 500 MCG TABLET

ROFLUMILAST
$0.3187per EA

Strength

500 ug/1

Manufacturer

Aurobindo Pharma Limited

NDC

59651027530

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

ROFLUMILAST

Approval Type

Generic (ANDA)

FDA Application

ANDA213298

On Market Since

4/17/2023

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price History

1W

0.0%

1M

+2.2%

3M

-5.3%

6M

+0.0%

1Y

-10.4%

3Y

N/A

5Y

N/A

All

-54.9%

Generic Alternatives

1 alternative • Same active ingredient

ROFLUMILAST 500 MCG TABLET
Generic
59651027590•Aurobindo Pharma Limited
$0.3187

Related Drugs

Same classification

ROFLUMILAST 500 MCG TABLET
Generic
00904739946•Major Pharmaceuticals
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
00904739989•Major Pharmaceuticals
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
00904748303•Major Pharmaceuticals
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
00904748389•Major Pharmaceuticals
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
31722062330•Camber Pharmaceuticals Inc.
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
31722062390•Camber Pharmaceuticals Inc.
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
42571025930•Micro Labs Limited
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
43547000503•Solco Healthcare US LLC
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
43547000509•Solco Healthcare US LLC
$0.3187
per EA
ROFLUMILAST 500 MCG TABLET
Generic
60687078621•American Health Packaging
$0.3187
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy